Skip to main content

Merendino Lauren's Form 4 filing

Day One Biopharmaceuticals, Inc.DAWN · filed May 19, 2025

Accession no.
0001415889-25-013687
Filed
May 19, 2025
Trade date
May 15-16, 2025
Filing delay
4 days
Rule 10b5-1 plan
Not checked

This filing lists 4 non-derivative transactions and 3 derivative transactions. Open-market sales total $24.6K. It was filed 4 days after the trade.

Reporting owners

A Form 4 can have several reporting owners, such as a person and a fund they control. Trade tables show the first one.

Reporting owners on this filing
OwnerRelationship to the company
Merendino LaurenCIK 0001855298Officer (Chief Commercial Officer)

Non-derivative securities (Table I)

Acquisitions and disposals of common stock and similar shares, one row per line on the filing.

Non-derivative transactions
Trade dateSecurityTransactionSharesPriceValueShares afterOwnershipFlags
May 15, 2025Common StockMOption exerciseAcquired+3,162–F1–31,714Direct
May 15, 2025Common StockMOption exerciseAcquired+3,687–F1–35,401Direct
May 15, 2025Common StockMOption exerciseAcquired+3,687–F1–39,088Direct
May 16, 2025Common StockSSaleDisposed−3,927$6.26F3−$24,583.0235,161Direct

Derivative securities (Table II)

Options, warrants, restricted stock units and similar. Shares are the underlying shares; price and value are for the derivative itself, and the holding after is in derivative units.

Derivative transactions
Trade dateSecurityTransactionUnderlying sharesUnit priceValueHeld afterOwnershipFlags
May 15, 2025Common StockMOption exerciseDisposed−3,162$0.00$028,464Direct
May 15, 2025Common StockMOption exerciseDisposed−3,687$0.00$036,878Direct
May 15, 2025Common StockMOption exerciseDisposed−3,687$0.00$051,626Direct

Footnotes and remarks

Livermore keeps the footnotes that transaction prices refer to, all footnotes of amendments (Form 4/A) and the filing's remarks. Other footnotes, such as how indirect holdings are held or the details of a trading plan, are only in the original on SEC EDGAR.

F1

Each Restricted Stock Unit ("RSU") represents a contingent right to receive one share of the Issuer's Common Stock upon settlement for no consideration.

Referenced by the price of 3 transactions in Table I.

F3

The price reported in Column 4 is a weighted average price. These shares were sold as part of block trades for multiple security holders of the Issuer at prices ranging from $6.19 to $6.32, inclusive. The Reporting Person undertakes to provide to the Issuer, any securityholder of the Issuer or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth herein with regard to the block trade.

Referenced by the price of 1 transaction in Table I.

Read the full filing on SEC EDGAR (opens in a new tab)